Hyderabad Telangana, India

Kanthikiran V S Varansi

This inventor holds 1 USPTO granted patent. Top assignee: Rhizen Pharmaceuticals Sa. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kanthikiran V S Varansi. Retrieved from https://idiyas.com/inventor/kanthikiran-v-s-varansi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Kanthikiran V S Varansi

Introduction:

Kanthikiran V S Varansi, a talented inventor based in Hyderabad, India, has made significant contributions to the field of healthcare with his groundbreaking patent. With a focus on developing novel therapies for non-small cell lung cancer (NSCLC), Kanthikiran is a leading figure in the pharmaceutical research industry.

Latest Patents:

Kanthikiran V S Varansi holds one patent titled "Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer." This patent discloses innovative calcium release-activated calcium (CRAC) channel inhibitors, their preparation methods, pharmaceutical compositions, and treatment methodologies for NSCLC. His research also extends to identifying therapeutics for cancer treatment and diagnosis.

Career Highlights:

Currently affiliated with Rhizen Pharmaceuticals SA, Kanthikiran leverages his expertise to drive forward the development of new pharmaceutical solutions. His dedication to advancing healthcare technologies reflects in his pioneering work on CRAC channel inhibitors for NSCLC treatment, showcasing his commitment to improving patient outcomes.

Collaborations:

Kanthikiran V S Varansi collaborates closely with esteemed colleagues in the field, such as Meyyappan Muthuppalaniappan and Srikant Viswanadha. Through teamwork and shared expertise, they collectively contribute to the cutting-edge research and development initiatives at Rhizen Pharmaceuticals SA.

Conclusion:

In conclusion, Kanthikiran V S Varansi stands as a prominent inventor in the healthcare sector, with a focus on enhancing cancer treatment through innovative pharmaceutical solutions. His patent on CRAC channel inhibitors for NSCLC underscores his commitment to advancing medical science and improving the lives of patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…